Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Factor Xa--a promising target for drug development.

Literature DB >> 11915937

Factor Xa--a promising target for drug development.

B Kaiser¹.

Abstract

Entities: Gene

Mesh：

Substances：

Year: 2002 PMID： 11915937 DOI： 10.1007/s00018-002-8415-9

Source DB: PubMed Journal: Cell Mol Life Sci ISSN： 1420-682X Impact factor: 9.261

Keyword Cloud
Cited

× No keyword cloud information.

7 in total

Review 1. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor.

Authors: Elisabeth Perzborn; Susanne Roehrig; Alexander Straub; Dagmar Kubitza; Frank Misselwitz
Journal: Nat Rev Drug Discov Date: 2010-12-17 Impact factor: 84.694

2. The impact of factor Xa inhibition on axial dependent arterial thrombus formation triggered by a tissue factor rich surface.

Authors: Nicholas Pugh; Gavin E Jarvis; Annelize Koch; Kjell S Sakariassen; Bill Davis; Richard W Farndale
Journal: J Thromb Thrombolysis Date: 2012-01 Impact factor: 2.300

3. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.

Authors: Charles E Frost; Wonkyung Byon; Yan Song; Jessie Wang; Alan E Schuster; Rebecca A Boyd; Donglu Zhang; Zhigang Yu; Clapton Dias; Andrew Shenker; Frank LaCreta
Journal: Br J Clin Pharmacol Date: 2015-05 Impact factor: 4.335

4. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.

Authors: Charles Frost; Sunil Nepal; Jessie Wang; Alan Schuster; Wonkyung Byon; Rebecca A Boyd; Zhigang Yu; Andrew Shenker; Yu Chen Barrett; Rogelio Mosqueda-Garcia; Frank Lacreta
Journal: Br J Clin Pharmacol Date: 2013-11 Impact factor: 4.335

Factor Xa--a promising target for drug development.

Review 1. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor.

2. The impact of factor Xa inhibition on axial dependent arterial thrombus formation triggered by a tissue factor rich surface.

3. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.

4. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.

5. Locally activity-released bifunctional fusion protein enhances antithrombosis and alleviates bleeding risk.

6. Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits.

7. Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.